Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trophos Program Boosted by EUR 1 Million Grant for Olesoxime in Progressive MS

Published: Friday, October 12, 2012
Last Updated: Friday, October 12, 2012
Bookmark and Share
Agence Nationale de la Recherche awards second grant to Trophos led consortium for Phase Ib/IIa clinical study.

Trophos SA has announced the award of a EUR 1 million grant to support the Translate-MS-Repair project.

The French 'Agence Nationale de la Recherche' (ANR) awarded the second successive grant to Trophos to target Multiple Sclerosis with olesoxime.

The funding will be provided under the Recherches Partenariales et Innovation Biomedicale 2012 program.

Translate-MS-Repair will be a 24 month project and will include a Phase Ib/IIa clinical study of olesoxime, Trophos' lead compound, to target neurodegeneration that underlies long term progressive disability in multiple sclerosis.

The project will be operated by a consortium spearheaded by Trophos including leading experts in Marseille (AP-HM/CNRS and CEMEREM-CRMBM), Rennes (CHU de Rennes and INRIA VISAGES) and Reims (CHU de Reims).

The clinical trial, which will be performed in 3 centers in France, will be led by Dr. Jean Pelletier AP-HM/CNRS-CEMEREM.

The clinical trial is designed to demonstrate the compatibility of olesoxime as a co-medication with existing treatments, the most frequent being beta interferon.

The study will also assess the feasibility of non-conventional magnetic resonance imaging procedures in a multicenter trial.

The clinical trial is designed to result in future large-scale clinical trials to assess efficacy of olesoxime to prevent progressive disability in MS patients.

"MS is the first cause of non-traumatic disability in young adults. While there are a number of effective treatments to control the relapsing inflammatory episodes, they have little effect on progressive disability in MS patients," said Rebecca Pruss, CSO, Trophos.

Pruss continued, "MS is a chronic inflammatory disease leading to demyelination and axonal degeneration in the central nervous system. However, it is now also recognized that MS is a neuro-degenerative disease as well. There is a real unmet need for agents to promote neuroprotection and myelin repair for MS."

"The second grant from the ANR to Trophos for our MS program is a recognition of the quality of Trophos' ongoing activity in neurodegenerative diseases within the Trophos pipeline," said Christine Placet, CEO, Trophos. "The ongoing success of olesoxime and the Trophos pipeline fits perfectly with Trophos strategy value creation."

Translate-MS-Repair is a sequel to the successful ANR funded MS-Repair project lead by Trophos and performed in collaboration with Aix-Marseille University and CNRS partners, IBDML (UMR 6216) and CRMBM (UMR 6612).

MS-Repair (ANR-08-BIOT-016-01) explored from 2008 to 2011 the activity of the molecule olesoxime in various in vitro and in vivo models of MS.

This project showed that the molecule is not only neuroprotective, but it has the ability to promote the maturation of oligodendrocyte progenitor cells (OPCs) into myelinating oligodendrocytes (details in Magalon et al, Ann Neurol. 2012 Feb;71(2):213-26).


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trophos Announces Top-Line Results in Pivotal Trial of Olesoxime in SMA
Promising results for the maintenance of motor function in spinal muscular atrophy - a rare, serious and debilitating pediatric-onset neurodegenerative disease.
Thursday, March 20, 2014
Trophos Completes Pivotal Phase II/III Study of Olesoxime in SMA
The French patients’ association AFM-Telethon supported the study which evaluates the ability of olesoxime to preserve the neuromuscular function of SMA patients.
Friday, November 08, 2013
Trophos Announces Final Patient Completion of Phase II Study of TRO40303
The study, a critical part of the EU funded MitoCare Project, will evaluate the reduction of reperfusion injury by TRO40303 in acute ST-elevation myocardial infarction (STEMI) patients.
Thursday, October 03, 2013
Trophos Launches First Study of Olesoxime in Multiple Sclerosis Patients
A Phase 1b study in RRMS patients is starting in three MS reference centers in France.
Tuesday, March 19, 2013
Trophos Announces Positive Interim Review in Pivotal Study of Olesoxime in SMA
Topline results expected in the fourth quarter of 2013.
Monday, March 04, 2013
Trophos Appoints JSB Partners as Global Partnership Advisor
Life science advisor to advise Trophos on strategic partnerships for orphan disease and niche indication candidates.
Monday, December 31, 2012
Marceline Clementine Appointed Chief Financial Officer
Ms. Clementine is now responsible for all administrative and financial services at Trophos.
Wednesday, September 19, 2012
Trophos Announces Conclusion of MitoTarget Consortium
EU funded 3-year project spearheaded by orphan disease specialist Trophos reports results from neurodegenerative program to the European Commission.
Wednesday, August 01, 2012
Trophos Appoints Christine Placet as Chief Executive Officer
Christine becomes CEO under a succession plan designed to provide continuity for Trophos.
Thursday, June 14, 2012
Trophos Announces Results of Phase III Study of Olesoxime in ALS
Company continues its ongoing programs and financed until at least the end of 2013.
Wednesday, December 14, 2011
Trophos Initiates Phase II Study for Novel Cardioprotective Compound, TRO40303, in Acute MI
European study being performed as part of Trophos-led, EU funded MitoCare project.
Tuesday, November 01, 2011
Trophos Completes Patient Enrolment in Pivotal Efficacy Study of Olesoxime in SMA
Topline results expected in second half of 2013.
Friday, September 09, 2011
Trophos Successfully Completes Phase 1 Study for Novel Cardioprotective Compound, TRO40303
Phase 2 proof-of-concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium.
Friday, February 25, 2011
Trophos to Lead new MitoCare Consortium Awarded EUR 6 Million to Study Cardioprotective Compound, TRO40303
Program of translational research to study innovative approaches to reducing cardiac ischemia-reperfusion injury.
Wednesday, December 15, 2010
Trophos and MS-Repair Partners Present Promising Data on Novel Approach in Multiple Sclerosis
Oral presentation at the Society for Neuroscience congress highlights novel compounds to promote axon repair and remyelination in multiple sclerosis.
Thursday, November 25, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!